Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron [Yahoo! Finance]
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain [Yahoo! Finance]
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
Dogwood Therapeutics (NASDAQ:DWTX) was downgraded by analysts at
Wall St
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight [Yahoo! Finance]